Cargando…
Delay Differential Model for Tumour-Immune Response with Chemoimmunotherapy and Optimal Control
We present a delay differential model with optimal control that describes the interactions of the tumour cells and immune response cells with external therapy. The intracellular delay is incorporated into the model to justify the time required to stimulate the effector cells. The optimal control var...
Autores principales: | Rihan, F. A., Abdelrahman, D. H., Al-Maskari, F., Ibrahim, F., Abdeen, M. A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4147205/ https://www.ncbi.nlm.nih.gov/pubmed/25197319 http://dx.doi.org/10.1155/2014/982978 |
Ejemplares similares
-
Chemoimmunotherapy triggers immune responses targeting microsatellite stable colorectal cancer
por: Thibaudin, Marion, et al.
Publicado: (2023) -
Delayed COVID-19 Respiratory Failure in Patients with Lymphoma on Rituximab-based Chemoimmunotherapy
por: Hoffmann, Marc S., et al.
Publicado: (2021) -
Complete response of metastatic gastric cancer to chemoimmunotherapy
por: Ina, Kenji, et al.
Publicado: (2017) -
Efficacy of chemoimmunotherapy with cyclophosphamide, interleukin-2 and lymphokine activated killer cells in an intraperitoneal murine tumour model.
por: Eggermont, A. M., et al.
Publicado: (1988) -
Dynamics of a stochastic delay differential model for COVID-19 infection with asymptomatic infected and interacting people: Case study in the UAE
por: Rihan, F.A., et al.
Publicado: (2021)